{"id":45385,"topic":"peptides","source":"USA Today","title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","url_hash":"87d3eb904b2bd149a86f80974ab917197774bc25","author":"","summary":"Is a peptide boom underway? FDA advisers vote for looser rules USA Today","content":"Is a peptide boom underway? FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community.\nIn a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.\nPeptides are short strings of amino acids, which are the body's building blocks of protein. Injectable versions of peptides are already being sold widely online for everything from muscle recovery to longevity via the unregulated or gray market.\nIn 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing \"potential significant safety risks\" by the agency.\nPotential adverse effects identified by the FDA include heart toxicity, infections, pancreatitis, increased or decreased insulin sensitivity, serious immunoresponses, melanoma and death. In most cases, the FDA said there was not ample testing or evidence to prove the peptides were safe or effective for use in humans.\nBut on Thursday, eight committee members voted in favor of adding the unapproved peptides BPC-157, KPV and TB-500. Six members voted no and one abstained.\nFor MOTs-C, which some use for obesity and osteoporosis, the vote was seven in favor, five against and two abstentions.\nAdvisers backing broader access argued that patients face safety risks when getting these products from the gray market while those who voted against said the decision should be based in science, not market-induced demand.\nMany of the panelists who voted yes have ties to the peptide industry, Reuters reports. Though a Department of Health and Human Services spokesperson told the outlet, \"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.\"\nHHS Secretary Robert F. Kennedy Jr. is a self-proclaimed proponent of peptides and has close ties to several vocal supporters and vendors of the compounds, including Gary Brecka and Dr. Mark Hyman, both of whom sell several products that say they contain beneficial peptides; and Brigham Buhler, a compounding pharmacy owner whom Kennedy previously hosted on his podcast.\nOn Friday, the advisers are set to vote on emideltide, also referred to as delta sleeping-inducing peptide or DSIP, Semax and Epitalon.\nAlthough the Pharmacy Compounding Advisory Committee's votes typically align with the FDA's final, legal decision on the matter, the agency does not have to follow the committee's recommendations.\nContributing: Reuters","image_url":"https://www.gannett-cdn.com/authoring/authoring-images/2026/01/16/USAT/88206510007-usatsi-26999167.jpg?auto=webp&crop=3935,2215,x0,y208&format=pjpg&width=1200","lang":"en","published_at":"2026-07-24T14:03:00+00:00","fetched_at":"2026-07-24T14:15:10+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community. In a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.","cluster_id":1689144,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}},"news_item":{"id":45385,"canonical_url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","source_url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","source_name":"USA Today","author":null,"published_at":"2026-07-24T14:03:00+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"Is a peptide boom underway? FDA advisers vote for looser rules USA Today","full_text":"Is a peptide boom underway? FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community.\nIn a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.\nPeptides are short strings of amino acids, which are the body's building blocks of protein. Injectable versions of peptides are already being sold widely online for everything from muscle recovery to longevity via the unregulated or gray market.\nIn 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing \"potential significant safety risks\" by the agency.\nPotential adverse effects identified by the FDA include heart toxicity, infections, pancreatitis, increased or decreased insulin sensitivity, serious immunoresponses, melanoma and death. In most cases, the FDA said there was not ample testing or evidence to prove the peptides were safe or effective for use in humans.\nBut on Thursday, eight committee members voted in favor of adding the unapproved peptides BPC-157, KPV and TB-500. Six members voted no and one abstained.\nFor MOTs-C, which some use for obesity and osteoporosis, the vote was seven in favor, five against and two abstentions.\nAdvisers backing broader access argued that patients face safety risks when getting these products from the gray market while those who voted against said the decision should be based in science, not market-induced demand.\nMany of the panelists who voted yes have ties to the peptide industry, Reuters reports. Though a Department of Health and Human Services spokesperson told the outlet, \"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.\"\nHHS Secretary Robert F. Kennedy Jr. is a self-proclaimed proponent of peptides and has close ties to several vocal supporters and vendors of the compounds, including Gary Brecka and Dr. Mark Hyman, both of whom sell several products that say they contain beneficial peptides; and Brigham Buhler, a compounding pharmacy owner whom Kennedy previously hosted on his podcast.\nOn Friday, the advisers are set to vote on emideltide, also referred to as delta sleeping-inducing peptide or DSIP, Semax and Epitalon.\nAlthough the Pharmacy Compounding Advisory Committee's votes typically align with the FDA's final, legal decision on the matter, the agency does not have to follow the committee's recommendations.\nContributing: Reuters","excerpt":"FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community. In a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 2790 characters.","diagnostics_url":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","summary":"FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community. In a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.","source":"USA Today","date":"2026-07-24T14:03:00+00:00","content":"Is a peptide boom underway? FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community.\nIn a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.\nPeptides are short strings of amino acids, which are the body's building blocks of protein. Injectable versions of peptides are already being sold widely online for everything from muscle recovery to longevity via the unregulated or gray market.\nIn 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing \"potential significant safety risks\" by the agency.\nPotential adverse effects identified by the FDA include heart toxicity, infections, pancreatitis, increased or decreased insulin sensitivity, serious immunoresponses, melanoma and death. In most cases, the FDA said there was not ample testing or evidence to prove the peptides were safe or effective for use in humans.\nBut on Thursday, eight committee members voted in favor of adding the unapproved peptides BPC-157, KPV and TB-500. Six members voted no and one abstained.\nFor MOTs-C, which some use for obesity and osteoporosis, the vote was seven in favor, five against and two abstentions.\nAdvisers backing broader access argued that patients face safety risks when getting these products from the gray market while those who voted against said the decision should be based in science, not market-induced demand.\nMany of the panelists who voted yes have ties to the peptide industry, Reuters reports. Though a Department of Health and Human Services spokesperson told the outlet, \"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.\"\nHHS Secretary Robert F. Kennedy Jr. is a self-proclaimed proponent of peptides and has close ties to several vocal supporters and vendors of the compounds, including Gary Brecka and Dr. Mark Hyman, both of whom sell several products that say they contain beneficial peptides; and Brigham Buhler, a compounding pharmacy owner whom Kennedy previously hosted on his podcast.\nOn Friday, the advisers are set to vote on emideltide, also referred to as delta sleeping-inducing peptide or DSIP, Semax and Epitalon.\nAlthough the Pharmacy Compounding Advisory Committee's votes typically align with the FDA's final, legal decision on the matter, the agency does not have to follow the committee's recommendations.\nContributing: Reuters","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 2790 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/45385","export_markdown":"/api/items/45385/export?format=markdown","export_json":"/api/items/45385/export?format=json","diagnose":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/"},"formats":{"full":{"id":45385,"title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","source":"USA Today","author":null,"published_at":"2026-07-24T14:03:00+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community. In a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.","full_text":"Is a peptide boom underway? FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community.\nIn a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.\nPeptides are short strings of amino acids, which are the body's building blocks of protein. Injectable versions of peptides are already being sold widely online for everything from muscle recovery to longevity via the unregulated or gray market.\nIn 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing \"potential significant safety risks\" by the agency.\nPotential adverse effects identified by the FDA include heart toxicity, infections, pancreatitis, increased or decreased insulin sensitivity, serious immunoresponses, melanoma and death. In most cases, the FDA said there was not ample testing or evidence to prove the peptides were safe or effective for use in humans.\nBut on Thursday, eight committee members voted in favor of adding the unapproved peptides BPC-157, KPV and TB-500. Six members voted no and one abstained.\nFor MOTs-C, which some use for obesity and osteoporosis, the vote was seven in favor, five against and two abstentions.\nAdvisers backing broader access argued that patients face safety risks when getting these products from the gray market while those who voted against said the decision should be based in science, not market-induced demand.\nMany of the panelists who voted yes have ties to the peptide industry, Reuters reports. Though a Department of Health and Human Services spokesperson told the outlet, \"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.\"\nHHS Secretary Robert F. Kennedy Jr. is a self-proclaimed proponent of peptides and has close ties to several vocal supporters and vendors of the compounds, including Gary Brecka and Dr. Mark Hyman, both of whom sell several products that say they contain beneficial peptides; and Brigham Buhler, a compounding pharmacy owner whom Kennedy previously hosted on his podcast.\nOn Friday, the advisers are set to vote on emideltide, also referred to as delta sleeping-inducing peptide or DSIP, Semax and Epitalon.\nAlthough the Pharmacy Compounding Advisory Committee's votes typically align with the FDA's final, legal decision on the matter, the agency does not have to follow the committee's recommendations.\nContributing: Reuters","reading_time_min":2,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 2790 characters.","diagnostics_url":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}},"actions":{"read":"/item/45385","export_markdown":"/api/items/45385/export?format=markdown","export_json":"/api/items/45385/export?format=json","diagnose":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/"}},"digest":{"id":45385,"title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","source":"USA Today","topic":"peptides","published_at":"2026-07-24T14:03:00+00:00","excerpt":"FDA advisers vote for looser rules A majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 2790 characters.","reading_time_min":2,"cluster_id":1689144},"card":{"display_title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","subtitle":"USA Today · 2026-07-24","summary":"FDA advisers vote for looser rules A majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing…","badges":["quality:high"],"links":{"read":"/item/45385","original":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","diagnose":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/"},"quality_warning":null},"export":{"title":"Is a peptide boom underway? FDA advisers vote for looser rules - USA Today","url":"https://eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","summary":"FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community. In a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.","source":"USA Today","date":"2026-07-24T14:03:00+00:00","content":"Is a peptide boom underway? FDA advisers vote for looser rules\nA majority of outside advisers for the Food and Drug Administration voted Thursday in support of allowing pharmacies to compound the first four of seven unapproved peptides, pleasing proponents in the wellness industry while raising concerns for some in the medical community.\nIn a two-day meeting that continues July 24, the FDA’s Pharmacy Compounding Advisory Committee has been considering these peptides, which have gained popularity for their purported health benefits.\nPeptides are short strings of amino acids, which are the body's building blocks of protein. Injectable versions of peptides are already being sold widely online for everything from muscle recovery to longevity via the unregulated or gray market.\nIn 2023, the FDA banned compounding pharmacies from producing specific peptides because they were identified as posing \"potential significant safety risks\" by the agency.\nPotential adverse effects identified by the FDA include heart toxicity, infections, pancreatitis, increased or decreased insulin sensitivity, serious immunoresponses, melanoma and death. In most cases, the FDA said there was not ample testing or evidence to prove the peptides were safe or effective for use in humans.\nBut on Thursday, eight committee members voted in favor of adding the unapproved peptides BPC-157, KPV and TB-500. Six members voted no and one abstained.\nFor MOTs-C, which some use for obesity and osteoporosis, the vote was seven in favor, five against and two abstentions.\nAdvisers backing broader access argued that patients face safety risks when getting these products from the gray market while those who voted against said the decision should be based in science, not market-induced demand.\nMany of the panelists who voted yes have ties to the peptide industry, Reuters reports. Though a Department of Health and Human Services spokesperson told the outlet, \"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members.\"\nHHS Secretary Robert F. Kennedy Jr. is a self-proclaimed proponent of peptides and has close ties to several vocal supporters and vendors of the compounds, including Gary Brecka and Dr. Mark Hyman, both of whom sell several products that say they contain beneficial peptides; and Brigham Buhler, a compounding pharmacy owner whom Kennedy previously hosted on his podcast.\nOn Friday, the advisers are set to vote on emideltide, also referred to as delta sleeping-inducing peptide or DSIP, Semax and Epitalon.\nAlthough the Pharmacy Compounding Advisory Committee's votes typically align with the FDA's final, legal decision on the matter, the agency does not have to follow the committee's recommendations.\nContributing: Reuters","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//eu.usatoday.com/story/news/health/2026/07/24/fda-peptides-rfk-jr/91033975007/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 2790 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 2790 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":2790,"summary_length":509,"usable_text_length":2790,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":2790,"summary_length":509}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}